Crinetics Pharmaceuticals
CRNX
240 hedge funds and large institutions have $5.19B invested in Crinetics Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 91 increasing their positions, 77 reducing their positions, and 28 closing their positions.
79% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 28
18% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 77
16% more capital invested
Capital invested by funds: $4.49B → $5.19B (+$708M)
7% more funds holding
Funds holding: 225 → 240 (+15)
3.23% more ownership
Funds ownership: 114.37% → 117.6% (+3.2%)
1% less call options, than puts
Call options by funds: $27.3M | Put options by funds: $27.6M
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$60.9M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$51.8M |
| 3 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$27.9M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$25.9M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$22.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$34M |
| 2 |
VPC
Vestal Point Capital
New York
|
-$31.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$28M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$15.3M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
-$15.1M |
CRNX Hedge Fund Activity: Q4 2025 in Review
240 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q4 2025, worth a combined $5.19B — up 16% from $4.49B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new CRNX positions and 28 closed out — a net gain of 22 holders — while 91 added to existing stakes and 77 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $60.9M. The largest seller was Jennison Associates, cutting an estimated $34M.
- 240 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q4 2025, up from 225 in Q3 2025.
- Funds reported $5.19B of Crinetics Pharmaceuticals stock for Q4 2025, up 16% quarter-over-quarter.
- 50 funds opened new Crinetics Pharmaceuticals positions in Q4 2025 and 28 closed out, a net change of +22 holders.
- The largest Crinetics Pharmaceuticals buyer in Q4 2025 was Baker Bros. Advisors, an estimated $60.9M added.
- The largest Crinetics Pharmaceuticals seller in Q4 2025 was Jennison Associates, an estimated $34M sold.
Based on aggregated 13F filings for Q4 2025.